Literature DB >> 27789547

Reversal of anticoagulation with four-factor prothrombin complex concentrate without concurrent vitamin K (phytonadione) for urgent surgery in a patient at moderate-to-high risk for thromboembolism.

Thomas Michael Farley1, Elisha M Andreas2.   

Abstract

Successful vitamin K antagonist (eg, warfarin) reversal with 4-factor prothrombin complex concentrate (4F-PCC) without vitamin K (phytonadione) for emergent surgery in a patient at moderate-to-high risk for thromboembolism is reported. This approach may decrease the risk for development of thrombus, as it limits the amount of time the patient's anticoagulation is subtherapeutic. It also may increase the risk of bleeding, so patient selection is essential if this strategy is employed. Caution must be exercised to complete the procedure or surgery in the window of peak 4F-PCC effect (∼1-6 hours postinfusion). 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27789547      PMCID: PMC5093848          DOI: 10.1136/bcr-2016-217092

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.

Authors:  Joshua N Goldstein; Majed A Refaai; Truman J Milling; Brandon Lewis; Robert Goldberg-Alberts; Bruce A Hug; Ravi Sarode
Journal:  Lancet       Date:  2015-02-27       Impact factor: 79.321

Review 2.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.

Authors:  Helmut Ostermann; Sabine Haertel; Sigurd Knaub; Uwe Kalina; Kerstin Jung; Ingrid Pabinger
Journal:  Thromb Haemost       Date:  2007-10       Impact factor: 5.249

Review 4.  Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations.

Authors:  Edith A Nutescu; William E Dager; James S Kalus; John J Lewin; Mark D Cipolle
Journal:  Am J Health Syst Pharm       Date:  2013-11-01       Impact factor: 2.637

5.  Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation.

Authors:  H Tran; M Collecutt; S Whitehead; H H Salem
Journal:  Intern Med J       Date:  2011-04       Impact factor: 2.048

6.  Using prothrombin complex concentrates to rapidly reverse oral anticoagulant effects.

Authors:  William E Dager
Journal:  Ann Pharmacother       Date:  2011-07-20       Impact factor: 3.154

7.  Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

Authors:  Ravi Sarode; Truman J Milling; Majed A Refaai; Antoinette Mangione; Astrid Schneider; Billie L Durn; Joshua N Goldstein
Journal:  Circulation       Date:  2013-08-09       Impact factor: 29.690

8.  Developing a management plan for oral anticoagulant reversal.

Authors:  William E Dager
Journal:  Am J Health Syst Pharm       Date:  2013-05-15       Impact factor: 2.637

9.  An evaluation of intravenous vitamin k for warfarin reversal: are guideline recommendations being followed?

Authors:  Ryan M Rivosecchi; Jeffrey Garavaglia; Sandra L Kane-Gill
Journal:  Hosp Pharm       Date:  2015-01
  9 in total
  1 in total

Review 1.  Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal.

Authors:  Jerrold H Levy; James Douketis; Thorsten Steiner; Joshua N Goldstein; Truman J Milling
Journal:  Anesthesiology       Date:  2018-12       Impact factor: 7.892

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.